Probiotic Vitamin D Composition for Faster Cholesterol-Neutral Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vitamin D deficiency and insufficiency are ineffective and slow, and therapies to lower blood cholesterol levels can further decrease vitamin D absorption, necessitating a rapid and effective solution to increase vitamin D bioavailability without raising cholesterol levels.
Innovation Solution
The use of specific isolated bacterial strains, particularly Lactobacillus paracasei, to enhance vitamin D absorption and bioavailability, combined with vitamin D supplementation, in compositions that are safe and cost-effective.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional vitamin D treatments are used, then vitamin D deficiency can be treated, but the treatment is ineffective and slow
Solution Approach 1:
The patent introduces bacterial strains (Lactobacillus paracasei, Lactobacillus plantarum, Bifidobacterium breve, Bifidobacterium animalis subsp. lactis, or Bifidobacterium bifidum) as intermediary substances that facilitate vitamin D absorption. These bacteria act as mediators between the vitamin D supplement and the intestinal epithelium, enhancing the absorption process and accelerating treatment effectiveness without extending treatment duration.
Solution Approach 2:
The patent modifies the absorption parameters of vitamin D by introducing bacterial strains that change the biochemical environment in the intestine. The bacteria produce substances that alter micelle formation, lipid digestion, and intestinal permeability, thereby changing the absorption rate and efficiency parameters to achieve faster and more effective treatment.
2Object-affected harmful factors
If therapies to lower blood cholesterol levels are used, then cardiovascular health is improved, but vitamin D absorption decreases
Solution Approach 1:
The bacterial strains serve as protective intermediaries that shield vitamin D absorption from inhibition by cholesterol-lowering therapies. The bacteria enhance the formation of micelles and facilitate lipid transport mechanisms that remain effective even when cholesterol absorption is suppressed, thus maintaining vitamin D levels while achieving cardiovascular health benefits.
Solution Approach 2:
The patent replaces the cholesterol-dependent absorption mechanism with a bacteria-mediated absorption pathway. Instead of relying on cholesterol-based micelle formation, the bacterial strains produce alternative surfactants and metabolic products that facilitate vitamin D absorption through different biochemical mechanisms, thereby substituting the absorption pathway to be independent of cholesterol-lowering drug effects.
3Quantity of substance
If vitamin D supplementation is increased to rapidly correct deficiency, then serum vitamin D levels rise quickly, but cholesterol levels may increase
Solution Approach 1:
The bacterial strains act as intermediaries that enable rapid vitamin D absorption without triggering cholesterol synthesis. The bacteria facilitate direct uptake of vitamin D into intestinal cells through enhanced membrane permeability and lipid transport mechanisms that do not depend on cholesterol metabolism, thus achieving rapid correction of deficiency while avoiding cholesterol elevation.
Solution Approach 2:
The patent substitutes the cholesterol-based absorption pathway with a bacteria-mediated mechanism that uses alternative lipid transport proteins and surfactant systems. This substitution allows high-dose vitamin D supplementation to be absorbed rapidly through non-cholesterol-dependent pathways, preventing the feedback loop that would otherwise raise cholesterol levels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bacterial strains effectively increase serum vitamin D levels and intestinal receptor expression, providing a rapid and cholesterol-neutral treatment for vitamin D deficiency and associated disorders.
Implementation Method 1
it enters the intestinal epithelium where it is incorporated into chylomicrons which enter the lymphatic circulation
Implementation Method 2
it is incorporated into the micelles formed by the meeting of hydrolysed lipids with bile
Implementation Method 3
Upon reaching the kidney, calcifediol (25(OH)2D) undergoes a hydroxylation reaction, catalysed by the enzyme 25(OH)D-1α-hydroxylase, giving rise to calcitriol (1,25-dihydroxycholecalciferol, abbreviated as 1,25(OH)2D)
Data Source
AI summary
The present invention relates to bacterial strains for use in the treatment of vitamin D deficiency and/or insufficiency and/or diseases, symptoms and/or disorders associated thereto. Furthermore, the present invention relates to compositions comprising at least one of said bacterial strains and at least one vitamin D, preferably vitamin D3, and to the use thereof in the treatment of said vitamin D deficiency and/or insufficiency and/or diseases, symptoms or disorders associated thereto.